felycin®-CA1

RAPACAT Trial

READ MANUSCRIPT

“Delayed-release rapamycin halts progression of left ventricular hypertrophy in subclinical feline hypertrophic cardiomyopathy: results of the RAPACAT trial”¹

Study Results:

When followed up over 6 months, untreated cats with subclinical HCM experience marked thickening (hypertrophy) of their left ventricle

Cats with higher levels of NTproBNP (a blood marker for cardiac disease) have more rapid progression of hypertrophy

Intermittent inhibition of mTOR prevented progression of hypertrophy

The HALT Study

The HALT HCM Study is a blinded, randomized, placebo-controlled trial of felycin®-CA1 in the management of ventricular hypertrophy associated with feline subclinical hypertrophic cardiomyopathy (HCM). The objective of the study is to provide substantial evidence of the effectiveness and safety of 12 months’ dosing of once-weekly felycin®-CA1 in feline subclinical HCM. The study is being conducted around 25 clinical sites across the United States that are experienced in treating cats with HCM. It will aim to enroll 300 cats.

Vet taking information with pet owner and cat

Take Part In Our Clinical Trials

TriviumVet is dedicated to raising the standard of treatment for some of the most serious medical conditions in pets. This requires quality clinical research, and for that we need your help. There are several different ways you can be part of our research driving therapeutic advances to enhance the lives of pets and the people who love them.

Having a pet with a serious health problem is frightening. Participating in a trial that is investigating a promising new therapy can not only provide hope for your pet, but it may also allow you and your pet to be part of research that brings hope to many more pets and owners.

View Our Clinical Trials